Olanzapine

Olanzapine is a second-generation antipsychotic of the thienobenzodiazepine chemical class ^[2]. It emerged from research into analogs of clozapine, an older and highly effective antipsychotic whose use is limited by a risk to the blood that demands regular monitoring; olanzapine was developed to retain broad efficacy without that particular constraint ^[2].

The drug was patented in 1991 and approved by the United States Food and Drug Administration in 1996, marketed by Eli Lilly under the brand name Zyprexa, and it became available as a generic in 2011 ^[1]. It appears on the World Health Organization's List of Essential Medicines.

Olanzapine's core approved uses are the treatment of schizophrenia, in both acute episodes and long-term maintenance, and bipolar disorder, particularly manic and mixed episodes ^[1]. It is also used together with fluoxetine for depressive episodes in bipolar disorder and for treatment-resistant depression, and it has become an important option for preventing nausea and vomiting caused by chemotherapy ^[3]. In comparative analyses it ranks among the more efficacious second-generation antipsychotics for schizophrenia, and systematic reviews have examined its benefit for associated symptoms such as anxiety ^[1][4]. In a randomized trial in patients receiving highly emetogenic chemotherapy, adding olanzapine to standard antiemetic drugs significantly improved control of nausea and vomiting ^[3].

The medicine is supplied in several forms, including standard oral tablets, orally disintegrating tablets, a short-acting intramuscular injection for acute agitation, and a long-acting injectable formulation for maintenance ^[1]. The long-acting injection carries a distinctive and rare risk called post-injection delirium or sedation syndrome, which requires that patients be observed for a period after each dose.

Olanzapine is a prescription medicine, and its defining drawback is its effect on metabolism ^[2]. It has one of the highest tendencies among antipsychotics to cause weight gain, and it is associated with raised blood sugar, an increased risk of type 2 diabetes, and abnormal blood lipids, effects that require monitoring during treatment ^[2]. It tends to cause sedation and, like other antipsychotics, carries a boxed warning about an increased risk of death when used in elderly patients with dementia-related psychosis ^[1].

Olanzapine is prescription only and carries a boxed warning about increased death rate when used for dementia-related psychosis in elderly patients, a use it is not approved for. Its standout drawback is metabolic; significant weight gain, rising blood sugar, new or worsening diabetes, and higher cholesterol are common, so weight, glucose, and lipids are monitored. Sedation, dizziness on standing, dry mouth, and constipation are frequent. Rare but serious risks include neuroleptic malignant syndrome, tardive dyskinesia with long use, and low white blood cell counts. The long-acting injection can rarely cause a post-injection sedation and delirium reaction, requiring observation after each dose.

Fluvoxamine, a potent inhibitor of the CYP1A2 enzyme that metabolizes olanzapine, causes a dose-dependent increase in olanzapine plasma concentration; the area under the curve rises 30 to 55 percent depending on fluvoxamine dose ^[29]. This is a pharmacokinetic interaction. The effect is clinically significant and requires careful monitoring and potential dose reduction. Smoking and nicotine also alter olanzapine levels, but in the opposite direction; they induce CYP1A2, increasing olanzapine clearance and reducing steady-state levels ^[30]. This too is pharmacokinetic. Patients who quit smoking may need lower olanzapine doses. The major gap: interactions with most anticonvulsants, anticholinergics, and non-SSRI antidepressants are not documented in controlled trials.

Checking a whole stack? Run it through interactions + stacks.

Olanzapine was developed by Eli Lilly and Company as part of a deliberate search for a compound with clozapine's efficacy but without that drug's risk of agranulocytosis and its attendant blood monitoring. A thienobenzodiazepine, it was first synthesized in the early 1990s and received United States Food and Drug Administration approval in 1996 for schizophrenia, later gaining indications for bipolar disorder. Its broad receptor-blocking profile proved highly effective, and it became one of the best-selling antipsychotics in the world under the brand name Zyprexa. More recently its potent antiemetic and appetite-stimulating effects, apparent even at very low doses, have been harnessed in cancer supportive care. To address its most troublesome liability, an olanzapine-samidorphan combination was developed to blunt the weight gain associated with the drug.

Olanzapine is one of the most effective and widely used atypical antipsychotics, valued for reliably controlling the symptoms of schizophrenia and bipolar mania and for a low tendency to cause the movement disorders that troubled older drugs. Beyond psychiatry it has won a devoted following in cancer care, where even very small doses are strikingly effective against chemotherapy-induced nausea and as an appetite stimulant. Its efficacy is not in doubt; the honest counterweight is metabolic. Olanzapine is among the antipsychotics most likely to cause weight gain, raised blood sugar, and lipid changes, which is precisely why strategies such as the olanzapine-samidorphan combination were created to blunt that effect. Used thoughtfully and with metabolic monitoring, it remains a mainstay of modern psychiatry and supportive oncology.